metabolic health

What does the evidence say about Safflower Oil Cardiometabolic Markers Randomized Trial?

Updated October 2026

Quick Answer

Safflower Oil Cardiometabolic Markers Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs.

Key Takeaways

  • 01However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs. [Laupsa-Borge J (2023)]
  • 02Background Clinical studies on effects of marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) on lipoprotein-lipid components and glucose-insulin homeostasis have shown conflicting results, which may partly be explained by differential responses in females and males. [Laupsa-Borge J (2023)]
The current Migaku evidence database contains 1 reusable source document for Safflower Oil Cardiometabolic Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs. [Laupsa-Borge J (2023); evidence level 2] - Background Clinical studies on effects of marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) on lipoprotein-lipid components and glucose-insulin homeostasis have shown conflicting results, which may partly be explained by differential responses in females and males. [Laupsa-Borge J (2023); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Learn next

Keep learning from this answer

GuideAshwagandha: What the Evidence Actually Says About Stress and CortisolLegacy library material — check the original sources.GuideMagnesium Glycinate benefits: what does the evidence sayLegacy library material — check the original sources.GuideProbiotics: What the Evidence Actually Supports (and What It Doesn't)Legacy library material — check the original sources.GuideL-Theanine: How It Works, What the Evidence Says, and How to Dose ItLegacy library material — check the original sources.DataSafflower Oil Lipids Randomized Trial Evidence TableLegacy library material — check the original sources.DataSafflower Oil Cardiometabolic Markers Randomized Trial Evidence TableLegacy library material — check the original sources.DataSafflower Oil Lipid Profile Randomized Trial Evidence TableLegacy library material — check the original sources.

Sources

  1. Sex-specific responses in glucose-insulin homeostasis and lipoprotein-lipid components after high-dose supplementation with marine n-3 PUFAs in abdominal obesity: a randomized double-blind crossover study.